Observations placeholder
Avastin and Bevacizumab
Identifier
017612
Type of Spiritual Experience
Background
A description of the experience
Bevacizumab trade name Avastin, Genentech is an angiogenesis inhibitor, a drug that slows the growth of new blood vessels.
Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A).[2] VEGF-A is a chemical signal that stimulates angiogenesis in a variety of diseases.
Bevacizumab was approved by the U.S. Food and Drug Administration (FDA) for certain metastatic cancers. It received its first approval in 2004, for combination use with standard chemotherapy for metastatic colon cancer. It has since been approved for use in certain lung cancers, renal cancers, ovarian cancers, and glioblastoma multiforme of the brain. It had been approved for breast cancer, but that approval was withdrawn when later studies showed no evidence of effectiveness.
It is also listed for its use in treating certain eye diseases
Many diseases of the eye, such as age-related macular degeneration (AMD) and diabetic retinopathy, damage the retina and cause blindness when blood vessels around the retina grow abnormally and leak fluid, causing the layers of the retina to separate. This abnormal growth is caused by VEGF, so bevacizumab is used to inhibit VEGF and slow this growth.
Bevacizumab has recently been used by ophthalmologists in an off-label [sic] use as an intravitreal agent in the treatment of proliferative (neovascular) eye diseases, particularly for choroidal neovascular membrane (CNV) in AMD.
Although not currently approved by the FDA for such use, the injection of 1.25-2.5 mg of bevacizumab into the vitreous cavity has been used
Results show similar outcomes using either bevacizumab or ranibizumab
Clinical trials are underway to test an intra-arterial technique for delivering the drug directly to brain tumors, bypassing the blood–brain barrier.
For treatment of eye diseases it is injected intravitreously.
On Dec, 29, 2016 42,902 people reported to have side effects when taking Avastin.
Among them, 96 people (0.22%) have Hallucination
Time on Avastin when people have Hallucination :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Hallucination | 60.00% | 0.00% | 0.00% | 40.00% | 0.00% | 0.00% | 0.00% |
On Dec, 23, 2016 42,902 people reported to have side effects when taking Avastin.
Among them, 9,896 people (23.07%) have Death
Time on Avastin when people have Death :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Death | 41.78% | 37.56% | 8.92% | 6.81% | 4.93% | 0.00% | 0.00% |
Gender of people who have Death when taking Avastin :
Female | Male | |
Death | 55.78% | 44.22% |
Age of people who have Death when taking Avastin :
0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
Death | 0.12% | 0.12% | 0.37% | 0.62% | 5.07% | 20.02% | 21.88% | 51.79% |
The source of the experience
eHealthmeConcepts, symbols and science items
Concepts
Symbols
Science Items
Activities and commonsteps
Activities
Overloads
CancerEye disease treatments - macular degeneration